Xuan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xuan Zhao has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Fanwei Xia
State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing 400716, China
1 shared publication - Hongjuan Cui
Medical Research Institute, State Key Laboratory of Resource Insects, Southwest University, Chongqing 400715, China
1 shared publication - Jie Xu
Cancer Center, Medical Research Institute, Southwest University, Chongqing 400716, China
1 shared publication - Junfan Chen
State Key Laboratory of Silkworm Genome Biology, Institute of Sericulture and Systems Biology, Southwest University, Chongqing 400716, China
1 shared publication - Liqun Yang
State Key Laboratory of Resource Insects, Medical Research Institute, Southwest University, Chongqing 400715, China; Jinfeng Laboratory, Chongqing 401329, China; Chongqing Engineering and Technology Research Center for Silk Biomaterials and Regenerative Medicine, Chongqing, 400716, China
1 shared publication - Pengfei Shi
Medical Research Institute, State Key Laboratory of Resource Insects, Southwest University, Chongqing, China
1 shared publication
Latest Publications
- Open Access
- 10 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 12036
RAI14 Promotes Melanoma Progression by Regulating the FBXO32/c-MYC Pathway
Melanoma originates from the malignant transformation of melanocytes. Compared with other skin cancers, melanoma has a higher fatality rate. The 5-year survival rate of patients with early-stage primary melanoma through surgical resection can reach more than 90%. However, the 5-year survival rate of patients with metastatic melanoma is only 25%. Therefore, accurate assessment of melanoma progression is critical. Previous studies have found that Retinoic Acid Induced 14(RAI14) is critical in tumorigenesis. However, the biological function of RAI14 for the development of melanoma is unclear. In this study, RAI14 is highly expressed in melanoma and correlated with prognosis. The expression of RAI14 can affect the proliferation, migration and invasion of melanoma cells. F-Box Protein 32(FBXO32) is an E3 ubiquitin ligase of c-MYC. We found that RAI14 affects the transcriptional expression of FBXO32 and regulates the stability of c-MYC. These results suggest that RAI14 play an important role in the growth of melanoma and is expected to be a therapeutic target for melanoma.
- 10 October 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (19) , 12036
Open AccessRAI14 Promotes Melanoma Progression by Regulating the FBXO32/c-MYC Pathway
Melanoma originates from the malignant transformation of melanocytes. Compared with other skin cancers, melanoma has a higher fatality rate. The 5-year survival rate of patients with early-stage primary melanoma through surgical resection can reach more than 90%. However, the 5-year survival rate of patients with metastatic melanoma is only 25%. Therefore, accurate assessment of melanoma progression is critical. Previous studies have found that Retinoic Acid Induced 14(RAI14) is critical in tumorigenesis. However, the biological function of RAI14 for the development of melanoma is unclear. In this study, RAI14 is highly expressed in melanoma and correlated with prognosis. The expression of RAI14 can affect the proliferation, migration and invasion of melanoma cells. F-Box Protein 32(FBXO32) is an E3 ubiquitin ligase of c-MYC. We found that RAI14 affects the transcriptional expression of FBXO32 and regulates the stability of c-MYC. These results suggest that RAI14 play an important role in the growth of melanoma and is expected to be a therapeutic target for melanoma.